SEC Company Response from vTv Therapeutics (VTVT) — Apr 16, 2021

vTv Therapeutics Inc.
Date: April 16, 2021 · CIK: 0001641489 · Accession: 0000950142-21-001304

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-254445

Date

April 16, 2021

Author

vTv Therapeutics

Form

CORRESP

Company

vTv Therapeutics Inc.

Letter

VIA EDGAR Division of Corporation Finance Securities and Exchange Commission Attention: Alan Campbell vTv Therapeutics Inc. Registration Statement on Form S-3 (File No. 333-254445)

Dear Mr. Campbell:

Pursuant to Rule 461 of the Securities Act of 1933, as amended, we hereby request that the effective date of the above-captioned Registration Statement on Form S-3 of vTv Therapeutics Inc. (the “Company”), be accelerated to April 20, 2021 at 4:00 p.m. Eastern Time or as soon thereafter as may be practicable.

We understand that the Staff will consider this request as confirmation by the Company of its awareness of its responsibilities under the federal securities laws as they relate to the issuance of the securities covered by the Registration Statement. If you have any questions regarding the foregoing, please contact Raphael M. Russo of Paul, Weiss, Rifkind, Wharton & Garrison LLP at (212) 373-3309.

*****

Very truly yours,
vTv Therapeutics
inc.

Show Raw Text

CORRESP
1
filename1.htm

vTv Therapeutics Inc.

3890 Premier Drive

Suite 310

High Point, NC 27265

April 16, 2021

VIA EDGAR

Division of Corporation Finance

Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

Attention: Alan Campbell

vTv Therapeutics Inc.

Registration Statement on

Form S-3 (File No. 333-254445)

Dear Mr. Campbell:

Pursuant to Rule 461 of the Securities Act of
1933, as amended, we hereby request that the effective date of the above-captioned Registration Statement on Form S-3 of vTv Therapeutics
Inc. (the “Company”), be accelerated to April 20, 2021 at 4:00 p.m. Eastern Time or as soon thereafter as may be practicable.

We understand that the Staff will consider this
request as confirmation by the Company of its awareness of its responsibilities under the federal securities laws as they relate to the
issuance of the securities covered by the Registration Statement. If you have any questions regarding the foregoing, please contact Raphael
M. Russo of Paul, Weiss, Rifkind, Wharton & Garrison LLP at (212) 373-3309.

*****

  Very truly yours,

  vTv Therapeutics
  inc.

  By:
  /s/ Rudy Howard

  Name:
    Rudy Howard

  Title:
    Chief Financial Officer

[Signature Page to Company Acceleration Request]

SecProbe.io